NEW PRECISION ONCOLOGY TEST
TO IDENTIFY THE MOST EFFECTIVE ANTI-CANCER TREATMENT

Patient Guide
Precisely match your cancer with the right targeted therapy

Oncofocus® is the world’s most comprehensive precision oncology test that precisely identifies the right drug for your cancer thereby increasing your chances of successful treatment.

Who will benefit?

Patients with widespread advanced cancers
Patients who have exhausted treatment options using conventional approaches such as chemotherapy and radiotherapy.

The Oncofocus® test can identify a broad range of additional therapeutic options for patients with advanced disease.

Patients with early cancers
Identifying optimal treatment options following initial diagnosis to achieve maximum benefit.

The Oncofocus® test can identify precisely the right anti-cancer drug and avoid the side effects and cost of drugs unlikely to be of benefit.

The test works by firstly sequencing the DNA and RNA of a patient’s tumour which has been extracted from the routine histology sample used for diagnosis.

The sequencing of DNA and RNA identifies genetic mutations specific to an individual’s tumour and generates a personalised genetic profile.

The detected mutations are then directly matched to the most appropriate anti-cancer drugs which have been designed to specifically target these particular mutations.

Over 600 targeted anti-cancer drugs

Applicable to all solid tumour types

Matching the right patient to the right anti-cancer drug
Oncologists at present act on limited information to try and match one of these anti-cancer drugs to an individual’s tumour and, given the vast array of different tumour types with very different genetic backgrounds, the probability of getting the correct match represents very low odds, accounting for cancer targeted drugs working in only 2-16% of patients. Using the Oncofocus® test, response rates to the new generation of targeted drugs can increase up to 85%.

There are over 600 targeted anti-cancer drugs which are either approved or being tested in clinical trials at present. There are hundreds of different tumour types all with different genetic mutations which all respond differently to these therapies.

Remove uncertainty from treatment decisions even in difficult cases

Treatment decisions for rare cancer types or cancers of unknown origin are challenging for your oncologist because of a lack of established therapeutic protocols.

The Oncofocus® test is ideally suited for the analysis of such cases enabling the precise matching of these tumours to the most appropriate therapy.

RESPONSE RATES OF TARGETED ANTI-CANCER DRUGS

2-16%

Targeted therapies given without testing

up to 85%

Targeted therapies identified by the Oncofocus® test

Cancers of unknown origin

Rare cancers

Difficult to treat and advanced cancers

Cancers not responding to conventional treatments
Monitor your disease over time

Following treatment by drugs identified by the Oncofocus® test it is possible over time that these patients become resistant to treatment.

This is because a proportion of tumour cells undergo further mutations allowing them to escape from the therapeutic effects of the anti-cancer drug.

However the Oncofocus® test can then be used for re-testing to identify these new genetic changes and allow new mutations to be directly matched to another set of anti-cancer drugs.

This approach can be compared to the treatment of bacterial disease with antibiotics in which treatment is switched following development of antibiotic resistance.

Why is the Oncofocus® Test better than existing tests?

Oncologists are frequently confounded by how to act on genetic results to benefit their patients because current genetic tests lack direct linkage with therapy.

Oncofocus® is a single test that links the majority of targeted anti-cancer drugs available, including FDA and EMA approved drugs or carrying NCCN and ESMO guideline references to virtually all cancer types.

The test also links a patient’s genetic profile with all targeted anti-cancer drugs currently in clinical trials (Phases I-IV) worldwide.

The Oncofocus® test is performed on the routine histology biopsy sample stored at your hospital and can be sent to us in the post. Other tests require specialist shipment and processing using fresh tissue.

If required, we also provide medical follow up support to position the patient with expert oncologists and to facilitate enrollment into clinical trials.
Example of how the Oncofocus® test precisely matches tumour type with the right targeted therapy

**Tumour profiling**

- Bladder
- Breast
- Colorectal
- Glioblastoma
- GIST
- Head and Neck
- Kidney
- Mesothelioma
- Non Small Cell Lung Cancer
- Oesophagus
- Pancreatic
- Prostate
- Soft Tissue Sarcoma
- Testicular
- Thyroid
- Ovarian
- Gastrointestinal Stromal Tumor (GIST)
- Mesothelioma
- Osteosarcoma
- Gastric
- Gastrointestinal Stromal Tumor (GIST)
- Small Cell Lung Cancer
- Pancreatic
- Testicular
- Thyroid
- Ovarian

**Detecting mutations**

- ALK FUSION
- BRAF MUTATION
- EGFR MUTATION
- PDGFRα AMPLIFICATION
- KIT FUSION
- CDKN2A MUTATION
- SMO MUTATION
- NTRK2 FUSION
- NTRK3 MUTATION
- ROS1 FUSION
- FGFR3 FUSION
- BRAF MUTATION
- PIK3CA AMPLIFICATION
- ERBB2 AMPLIFICATION
- PIK3CA AMPLIFICATION
- ERBB2 AMPLIFICATION
- PIK3CA AMPLIFICATION
- ERBB2 AMPLIFICATION
- PIK3CA AMPLIFICATION
- ERBB2 AMPLIFICATION
- PIK3CA AMPLIFICATION
- ERBB2 AMPLIFICATION
- PIK3CA AMPLIFICATION
- ERBB2 AMPLIFICATION
- PIK3CA AMPLIFICATION
- ERBB2 AMPLIFICATION
- PIK3CA AMPLIFICATION
- ERBB2 AMPLIFICATION

**Matching mutations with the right therapy**

- IMATINIB MESYLATE
- CRIZOTINIB
- VEMURAFENIB
- AFATINIB
- DABRAFENIB
- NERATINIB
- COBIMETINIB + RG-7446
- VORINOSTAT
- CABOZANTINIB

---

**Oncofocus: Precise Tumour Profiling**

- ALK FUSION
- BRAF MUTATION
- EGFR MUTATION
- PDGFRα AMPLIFICATION
- KIT FUSION
- CDKN2A MUTATION
- SMO MUTATION
- NTRK2 FUSION
- NTRK3 MUTATION
- RET MUTATION
- ERBB2 AMPLIFICATION
- PIK3CA AMPLIFICATION
- ERBB2 AMPLIFICATION
- PIK3CA AMPLIFICATION
- ERBB2 AMPLIFICATION

---
How to order the Oncofocus® Test

Download the Oncofocus® Test Request form from our website at http://www.oncologica.com/request-a-test

Enclose the completed Form and a copy of the pathology report with the routine histology biopsy sample to be tested.

When the parcel is ready call us on +44 (0)1223 785327 to arrange a pick up using our FREE international courier service.

Once the sample has been received at Oncologica the test is carried out and the clinical report issued within 10 working days.

Oncologica is at the forefront of providing precision oncology services that can help ensure that patients derive maximum benefit from the new generation of personalised anti-cancer drugs.

PATIENT / CLINICIAN CUSTOMER SERVICE
+44 (0)1223 785327

patientcare@oncologica.com
www.oncofocus.org
NEW PRECISION ONCOLOGY TEST
TO IDENTIFY THE MOST EFFECTIVE ANTI-CANCER TREATMENT

Applicable to all solid tumours
Performed on Routine Histology samples

Oncofocus® REPORT INCLUDES
FDA and EMA approved therapies
ESMO and NCCN references
Therapies in clinical trials worldwide

Suite 15-16, The Science Village, Chesterford Research Park
Cambridge, CB10 1XL
www.oncologica.com